Elliot Bland
About
Elliot Bland is from Buckhurst Hill, England, United Kingdom. Elliot works in the following industries: "Pharmaceutical Manufacturing". Elliot is currently Vice President Operations at iosBio, located in United Kingdom. Elliot also works as Senior Research Fellow [visiting] at Queen Mary University of London, a job Elliot has held since Dec 2016. In Elliot's previous role as a Business Development and Technology Transfer Manager at Queen Mary Innovation Ltd, Elliot worked in London, United Kingdom until Nov 2016. Prior to joining Queen Mary Innovation Ltd, Elliot was a Business Development Manager (Global) at S.L.A. Pharma and held the position of Business Development Manager (Global) at Watford, United Kingdom. Prior to that, Elliot was a Business Development Manager at NHS Innovations London Ltd, based in London, United Kingdom from Jan 2008 to Jan 2010. Elliot started working as Partnership Liaison Manager at NHS Innovations London Ltd in London, United Kingdom in Jan 2007. From Jan 2006 to Jan 2007, Elliot was Business Consultant at Theragenetics Ltd, based in London, United Kingdom. Prior to that, Elliot was a Project Manager at Cell Analysis Ltd, based in York, United Kingdom from Jan 2004 to Jan 2006. Elliot started working as Senior Scientist at AstraZeneca in Jan 2003.
You can find Elliot Bland's email address at finalscout.com. FinalScout is a free professional database with over five hundred million business professional profiles and over two hundred million company profiles.
Elliot Bland's current jobs
Elliot Bland's past jobs
QMI Ltd provides innovation management and commercialisation services to Queen Mary University of London and Barts Health Trust. • Generated over 50% of company licence income 2013-2014, 2014-2015 and 2015-2016. • Identification, analysis and evaluation (scientific, IP, commercial) of novel technologies. • Business development: targeting and connecting with potential partners for out-licensing and collaboration activities, financial modelling, negotiating to conclusion various agreements (e.g. licensing, collaboration). • Put together non-clinical package for submission to MHRA, negotiated supply of API and finished product to enable Phase IIa study in trauma. • Developed nonclinical safety plans for various programmes, submitted to and agreed by MHRA. • Provide guidance to researchers on non-clinical and clinical study design to build robust data-package. • Implemented electronic filing system to ensure project data is stored and accessible. • Aided in gaining £2m+ in external translational funding for projects.
SLA Pharma is a speciality pharmaceutical company focusing on gastrointestinal diseases with unmet needs and orphan diseases. • Out-licensed phase III development to pan-European company. • Generated significant company income through licensing activities. • Updated in-house financial modelling process to evaluate market potential and deal terms. • Leading on all business development activities including: targeting and building relationships with potential partners, preparing term sheets and negotiating licensing agreements to conclusion. • Organising and managing due-diligence. • Defining commercial strategy, creating marketing literature for licensing opportunities. • Developing and implementing an online strategy to enhance company profile. • Reporting directly to CEO.
SME providing innovation management, product development and commercialisation services to the NHS. • Business development and licensing negotiations with industry for commercialisation of new technologies. • Worked alongside Director of Business Development, licensing over 30 new developments. • Out-licensed the company’s first medical device innovation, plus other developments in cardiology, neurology, emergency medicine, OBGY, diagnostics, and software. • Helped raise £0.75m funding for a cardiology start-up company. • Designed and implemented a financial forecasting model to assess the viability of new technologies. • Aided in delivery of 10-day consultation programme to CSIR (South African governmental R&D program) on pipeline development, innovation assessment and product commercialisation.
SME providing innovation management, product development and commercialisation services to the NHS. • Performed patent and FTO reviews, technical analysis, market and financial evaluation of innovations. • Developed relationships with university technology transfer, KOLs and key influencers to discover innovative developments and evaluate for investment. • Worked with hospital executives to increase in-house innovation pipeline. • Successfully applied for over £0.5m in proof-of-concept funding. • Commissioned a regional marketing campaign to increase awareness of NHS Innovations London. • Aided in the development of a high throughput stage-gate innovation review process for the NHS.
Personalised Medicine Diag. Co.; developing and commercialising a portfolio of pharmacogenetic diagnostics. • Carried out a market review of pharmacogenetic testing for anti-psychotic drug response including analysis of competitive/complementary technologies, potential investors and M&A targets. • Supported CEO in preparing presentations and business plans for Series A financing, raising £3m.
Provides identification services and products: from human genetic disorders to agricultural breed genetics. • Led a team of five staff to develop and commercialise a new SNP detection technology. • Successfully diversified business towards agricultural identification services, generating new revenues. • Initiated and closed the company’s first sales. • Developed commercial relationships with leading diagnostic companies.
• Worked on site at AstraZeneca as part of a commercial collaboration. • Developed dielectrophoresis device from ‘proof of principle’ to functional instrument.